- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT01119131
Effects of Vitamin D in Parkinson's Disease (PD)
8. februar 2016 oppdatert av: VA Office of Research and Development
The Effects of Vitamin D on Balance in Persons With PD
A trial to measure the effects of vitamin D (versus a placebo) on balance, gait, falls, strength, and cognition in persons with Parkinson's disease.
Studieoversikt
Status
Fullført
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
The proposed study is a randomized, double-blinded, placebo controlled intervention trial to measure the effects of vitamin D at (10,000IU/day) versus placebo on balance and falls in Parkinson's disease.
The investigators will measure static, dynamic, and ambulatory balance, as well as strength, falls, and cognition before and after 16 weeks of therapy.
Dynamic posturography will be used to measure static and ambulatory balance, a device called iMOBILITY will measure a timed up and go, and strength will be measured with the Biodex machine checking knee flexion and extension.
Multiple quality of life and cognitive tests will also be performed.
Studietype
Intervensjonell
Registrering (Faktiske)
101
Fase
- Fase 2
Kontakter og plasseringer
Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.
Studiesteder
-
-
Oregon
-
Portland, Oregon, Forente stater, 97239
- VA Portland Health Care System, Portland, OR
-
-
Deltakelseskriterier
Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
50 år til 99 år (Voksen, Eldre voksen)
Tar imot friske frivillige
Nei
Kjønn som er kvalifisert for studier
Alle
Beskrivelse
Inclusion Criteria:
- Parkinson's disease;
- ability to ambulate 50 feet;
- ability to cooperate with balance testing;
- vitamin D level less than 40ng/ml;
- balance problems;
- ability to walk 50 feet without the help of another person
Exclusion Criteria:
- MMSE < 25;
- another neurological or orthopedic deficit that in the examiner's opinion would affect testing;
- history of renal stones or hypercalcemia;
- unwillingness to not be on other vitamin D supplementation during the study
Studieplan
Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Firemannsrom
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Aktiv komparator: Arm 1
Will be on high dose vitamin D3 (10,000 IU daily) and 1000 mg of calcium
|
Vitamin D3 at 10,000 IU a day
1000mg calcium daily
|
|
Placebo komparator: Arm 2
Will be on placebo and 1000mg of calcium.
|
1000mg calcium daily
A placebo pill with similar appearance to the vitamin D3 will be given to those in the placebo arm
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Change in Static Balance as Recorded Using Dynamic Posturography With the Sensory Organization Test (SOT 1-3)
Tidsramme: Baseline, 16 weeks
|
Sensory organization test (SOT) is a form of posturography.
which is designed to assess quantitatively an individual's ability to use visual, proprioceptive and vestibular cues to maintain postural stability in stance.
The SOT measures sway during 6 scenarios.
In scenarios 1-3 the base is stable and eyes are open, then closed, and then the visual surround moves.
SOT 1-3 is an average measurement of equilibrium - the average center of gravity sway for each condition.
It generates a score of 0 (fall) up to 100 for each scenario and an overall composite score.
Change score is measurement at 16 weeks minus measurement at baseline.
|
Baseline, 16 weeks
|
|
Change in Ambulatory Balance Measured by Instrumented Timed up and go (iTUG) Turn Duration
Tidsramme: Baseline and 16 weeks
|
This is a test that measures ambulatory balance and mobility.
The instrumented timed up and go (iTUG) is an average time (seconds) of three trials that involve the participant arising from a chair, walking 25 feet turning around, walking back to the chair, and sitting down.
The turn duration is the average time to turn at the end of the 25 foot walk.
Longer duration of time (seconds) indicates more rigidity, a proxy measure for "ON" time in Parkinson's disease.
Change score is measurement at 16 weeks minus measurement at baseline.
|
Baseline and 16 weeks
|
|
Change in Strength as Recorded by Measuring Knee Flexion Using Biodex (Total Work)
Tidsramme: Baseline, 16 weeks
|
Defined as the total muscular force output for the repetition with the greatest amount of work.
The equation for work is: W = F x D. Change score is measurement at 16 weeks minus measurement at baseline.
|
Baseline, 16 weeks
|
|
Change in Dynamic Balance as Recorded Using Dynamic Posturography With the Sensory Organization Test (SOT 4-6)
Tidsramme: Baseline, 16 weeks
|
Sensory organization test (SOT) is a form of posturography.
which is designed to assess quantitatively an individual's ability to use visual, proprioceptive and vestibular cues to maintain postural stability in stance.
The SOT measures sway during 6 scenarios.
In 4-6 the base moves and the subject has eyes open, then closed, then the visual surround moves.
SOT 4-6 is an average measurement of equilibrium - the average center of gravity sway for each condition.
It generates a score of 0 (fall) up to 100 for each scenario and an overall composite score.
Change score is measurement at 16 weeks minus measurement at baseline.
|
Baseline, 16 weeks
|
|
Change in Strength as Recorded by Measuring Knee Extension Using Biodex (Total Work)
Tidsramme: Baseline, 16 weeks
|
Defined as the total muscular force output for the repetition with the greatest amount of work.
The equation for work is: W = F x D. Change score is measurement at 16 weeks minus measurement at baseline.
|
Baseline, 16 weeks
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Change in Cognition (Trail Making Test B-A)
Tidsramme: Baseline, 16 weeks
|
The Trail Making Test (TMT) consists of two parts (A & B) in which the subject is instructed to connect a set of 25 dots as quickly as possible while still maintaining accuracy.
The test provides information about visual search speed, scanning, speed of processing, and executive functioning.
Part A measures processing speed and part B measures executive functioning.
The TMT is time to complete each part of the test in seconds.
Higher scores indicate greater impairment.
Subtracting part A from part B is theorized to reduce the influence of the working memory and visuospatial demands and, therefore, provides a relatively pure indicator of executive function.
Change score is measurement (Part B - Part A) at 16 weeks minus measurement (Part B - Part A) at baseline, negative scores indicate a improvement in executive functioning.
|
Baseline, 16 weeks
|
|
Change in Quality of Life as Recorded Using Quality of Life Scales (PDQ39)
Tidsramme: Baseline, 16 weeks
|
The PDQ39 is a 39 item patient completed survey targeting well-being and functioning in PD.
This scale address 8 dimensions (mobility, activities of daily living, emotional well-being, stigma, social support, cognitions, communication, and bodily discomfort).
The PDQ39 dimension scores are on a scale of 0 ("Never") to 4 ("Always/Cannot Do").
Scale scores are summed and range from 0 to 100 with 100 being the maximum level of problems.
For a single index figure to characterize the impact of Parkinson's disease upon PD patients (PDSI), all 39 items of the PDQ39 can be summed.
The PDQ39 and the use of a PDSI have shown adequate reliability and convergent validity.
Change score is measurement at 16 weeks minus baseline measurement, negative scores indicate an improvement in quality of life.
|
Baseline, 16 weeks
|
|
Change in Parkinsonism as Measured by the UPDRS
Tidsramme: Baseline, 16 weeks
|
This is the motor subsection of the UPDRS and is a commonly used tool to rate the symptoms of Parkinson's disease.
This scale rates from 0 (normal) to 4 (Can barely perform the task) several motor areas including speech, facial expression, tremor, rigidity, hand movements, agility, posture, and gait.
A sum score represents motor function with higher values on this scale represent a more severe stage of the disease.
Change is measurement at 16 weeks minus baseline measurement, negative scores indicate an improvement in Parkinson's motor symptoms.
|
Baseline, 16 weeks
|
Samarbeidspartnere og etterforskere
Det er her du vil finne personer og organisasjoner som er involvert i denne studien.
Samarbeidspartnere
Etterforskere
- Hovedetterforsker: Amie Hiller, MD BS, VA Portland Health Care System, Portland, OR
Publikasjoner og nyttige lenker
Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.
Studierekorddatoer
Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.
Studer hoveddatoer
Studiestart
1. mai 2011
Primær fullføring (Faktiske)
1. januar 2015
Studiet fullført (Faktiske)
1. januar 2015
Datoer for studieregistrering
Først innsendt
23. april 2010
Først innsendt som oppfylte QC-kriteriene
5. mai 2010
Først lagt ut (Anslag)
7. mai 2010
Oppdateringer av studieposter
Sist oppdatering lagt ut (Anslag)
7. mars 2016
Siste oppdatering sendt inn som oppfylte QC-kriteriene
8. februar 2016
Sist bekreftet
1. februar 2016
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
- Hjernesykdommer
- Sykdommer i sentralnervesystemet
- Sykdommer i nervesystemet
- Parkinsonlidelser
- Basal ganglia sykdommer
- Bevegelsesforstyrrelser
- Synukleinopatier
- Nevrodegenerative sykdommer
- Parkinsons sykdom
- Fysiologiske effekter av legemidler
- Mikronæringsstoffer
- Vitaminer
- Bone Density Conservation Agents
- Kalsiumregulerende hormoner og midler
- Vitamin d
- Kolekalsiferol
- Kalsium
Andre studie-ID-numre
- B7051-W
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .